Phase 1 Rheumatoid Arthritis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are generally healthy, as confirmed by a doctor reviewing your medical history, a physical check-up, and lab tests done during the screening process.
- You are willing and able to attend all required study visits and follow the study's rules.
If you have Rheumatoid Arthritis (RA):
- You have been diagnosed with RA and meet the standard 2010 classification criteria for RA (confirm with trial site).
- You have a positive blood test result for rheumatoid factor or a related antibody (ACPA) above the normal range.
- Your RA is at least moderately active, shown by at least 6 swollen and 6 tender joints, OR at least 3 joints with active inflammation seen on an MRI scan.
If you have Lupus (SLE):
- You have been diagnosed with SLE and meet the standard 2019 classification criteria for SLE (confirm with trial site).
- You have a positive ANA blood test at a level of 1:80 or higher, plus at least one other specific antibody (anti-dsDNA or anti-Smith) above the normal range.
Who may not be able to join:
- You have significant problems with how an organ is working, or your physical exam, vital signs, or lab results are notably outside the normal range for a healthy person.
- You have taken part in another drug or medical device trial, or used an experimental drug, within the past 30 days (or longer, depending on the drug) before starting this study.
If you have Rheumatoid Arthritis (RA):
- You have been diagnosed with Felty's syndrome (a complication of RA involving a low white blood cell count and an enlarged spleen).
If you have Lupus (SLE):
- You currently have, or have had within the last 6 months, lupus affecting your brain or nervous system (for example, confusion, seizures, or mood changes linked to lupus) — though lupus-related headaches may be acceptable (confirm with trial site).
- Additional criteria not listed here may also apply (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 844-663-3742
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of participants with changes in the safety parameters; Number of participants with clinical laboratory assessment abnormalities; Number of participants with changes in the vital signs; Number of participants with changes in the ECG; Number of participants who develop anti-drug antibodies (ADAs) and Circulating Immune Complex (CIC) formation; Part A and B: Number of participants with change from baseline in vaccine antibody titers; Changes in serum cytokine and chemokine levels that are known to be associated with CAR-T cell therapy related toxicity; Change from baseline in soluble immun...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.